Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer|Metastatic Breast Cancer|Metaplastic Breast Carcinoma|TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: L-NMMA
Sponsor: The Methodist Hospital Research Institute
Collaborators: Novartis Pharmaceuticals